NCC Medical Debuts at MEDICA 2025 : Deepening Global Cooperation, CE Certification Empowers New International Journey

MEDICA 2025 Düsseldorf, the world's top event in the medical industry, concluded successfully from November 17 to 20.

     NCC Medical showcased its core strengths at this industry platform known as the "benchmark of global medical trade fairs". During the four-day exhibition, the company conducted in-depth meetings with over 70 global distributors (covering more than 30 countries including Brazil, Turkey, Iran, South Korea, Japan, and Germany), successfully expanded new distributor partnerships, and established professional communication channels with international top electrophysiology technicians and clinicians. Notably, the company's core products — IONM, EEG, and EMG — are about to officially obtain CE MDR Certification, laying a key foundation for its global market layout.

Focusing on the Global Market and Connecting Core Resources

     With the theme of "Meet Health · Future · People", this year's MEDICA gathered 4,800 exhibitors from 160 countries and over 78,000 professional visitors, covering the entire industrial chain including medical equipment, diagnostic technology, and physical therapy. 

     As an enterprise deeply engaged in the medical field, NCC Medical leveraged the exhibition platform to conduct annual strategic alignment with existing distributors in Europe, the Middle East, Southeast Asia, and other regions, and held pragmatic discussions on core topics such as product adaptability and localized services. Coupled with the support of the CE Certificate, the company has taken an important step in the process of compliant international market expansion, providing solid guarantees for continuously deepening regional market cooperation.

Expanding Cooperation Boundaries and Building a Multi-Dimensional Communication Ecosystem

     During the exhibition, NCC Medical's booth attracted a large number of potential partners for discussions, and the company successfully signed contracts with several new distributors, further improving the layout of its global distribution network. It also focused on launching the innovative marketing strategy of "Buy Consumables, Get Free IONM System" and the advantages of the integrated platform of "Equipment + Consumables + Services + Training". Such flexible cooperation models have received widespread attention and positive responses from global partners.

     It is worth noting that experts and clinicians in the field of electrophysiology from Germany, France, Spain, and other countries took the initiative to visit the booth and conducted in-depth discussions on topics such as technical application scenarios and the upgrading of clinical needs. This communication achievement echoes positively with the current industry trend of accelerated internationalization of global electrophysiological devices.

Anchoring International Vision and Deepening Global Strategy

     As a weather vane of global medical innovation, the MEDICA exhibition has built a crucial bridge for us to connect with global demands. The head of NCC Medical's Overseas Business says : "Obtaining the CE Certification has enhanced the international competitiveness of our products, while the innovative model of 'Buy Consumables, Get Free IONM System' creates greater value for our partners. This exhibition not only enabled in-depth engagement with over 70 distributors (covering more than 30 countries) but also allowed us to accurately grasp the development pulse of global medical technology through in-depth dialogues with international peers. In the future, taking this exhibition as an opportunity, the company will continue to optimize its product and service system to provide more valuable medical solutions for global customers."

     This participation in MEDICA is an important practice of NCC Medical's global strategy. In the follow-up, the company will advance the implementation of the cooperation intentions reached at the exhibition and continue to empower the development of global medical and health undertakings.

About NCC Medical Co.,Ltd

     For 28 years, NCC Medical has focused on tackling key challenges in electrophysiological technology and developing related products. Adhering to the core value of "Commitment,Sincerity,Integrity," the company has continuously launched high-end electrophysiological equipment with independent intellectual property rights, driving the development of the electrophysiology industry. Its independently developed product—the first domestically made neurostimulation monitor specifically designed for intraoperative use in orthopedics and neurosurgery—has achieved a major breakthrough in domestic manufacturing and broken the barrier of reliance on imported equipment. Looking ahead, in the field of intraoperative electrophysiology, NCC Medical aims to strengthen industry-academia-research cooperation with clinical institutions, advance the development of cutting-edge technologies in this field, and provide higher-quality services for patients.

     As a "National-level Specialized, Refined, Differential, and Innovative Little Giant Enterprise" recognized by the Ministry of Industry and Information Technology, NCC Medical has always adhered to independent innovation and lean manufacturing, and built a full-chain independent and controllable system covering core technology R&D to key component production. The company's consumables subsidiary, Shanghai Yingshou Medical Device Co., Ltd., has also been awarded the title of "Shanghai Municipal-level Specialized, Refined, Differential, and Innovative Little Giant Enterprise", which further strengthens the company's leading advantages in the collaborative innovation of equipment and consumables.

     NCC Medical attaches great importance to technological innovation and clinical value. Its independently developed intraoperative  neuromonitoring and 256 high-channel event-related potential digital EEG capable of assisting cognitive diagnosis have both been included in the Shanghai Innovative Medical Devices Catalog . This marks that the products have obtained authoritative recognition in terms of technological advancement, clinical urgency, and quality and safety standards.